hapabapa/iStock Editorial via Getty Images
The US Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by Bristol-Myers Squibb (New York Stock Exchange:BMY), as a new treatment for adults with schizophrenia, a psychiatric disorder.
Bristol-Myers (BMY) is trading ~5% higher in